A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

URN to cite this document:: urn:nbn:de:bvb:355-epub-505667
DOI to cite this document:: 10.5283/epub.50566

Weissinger, Eva M. ; Metzger, Jochen ; Schleuning, Michael ; Schmid, Christoph ; Messinger, Diethelm ; Beutel, Gernot ; Wagner-Drouet, Eva-Maria ; Schetelig, Johannes ; Baurmann, Herrad ; Rank, Andreas ; Stolzl, Friedrich ; Schäfer-Eckart, Kerstin ; Westphal, Karin ; Bethge, Wolfgang ; von Harsdorf, S. ; Bunjes, Donald W. ; Heidenreich, Daniela ; Klein, Stefan ; Holler, Ernst ; Kreipe, Hans H. ; Jonigk, Danny ; Türüchanow, Irina ; Raad, Julia ; Papkalla, Armin ; von der Leyen, Heiko ; Hambach, Lothar ; Hamwi, Iyas ; Ehrlich, Steve ; Krauter, Jürgen ; Stadler, Michael ; Ganser, Arnold

License: Creative Commons Attribution 4.0
PDF - Published Version
(727kB)

Date of publication of this fulltext: 11 Oct 2021 13:08

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Acute graft-versus-host disease (aGvHD) contributes to about 50% of transplant-related mortality (non-relapse mortality) after allogeneic hematopoietic stem cell transplantation (HSCT). Here the predictive value of a urinary proteomic profile (aGvHD_MS17) was tested together with preemptive prednisolone therapy. Two-hundred and fifty-nine of 267 patients were eligible for analysis. Ninety-two ...